Tag: Alzheimer’s

FDA Warns 17 Companies for Selling Nonapproved Medicine

The U.S. Food and Drug Administration today posted 12 warning letters and 5 online advisory letters issued to foreign and domestic companies that are illegally selling more than 58 products, many that...

Roche and AC Immune Stop Trials of Alzheimer’s Drug

Roche and AC Immune have discontinued phase III trials of their Alzheimer’s disease drug crenezumab after an interim analysis indicated it would not hit its primary endpoint. Crenezumab is an anti-...

Generic for Alzheimer’s and Parkinson’s Approved by FDA

The U.S. Food and Drug Administration (FDA) approved Bridgewater, NJ-based Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to A...

Biogen to Expand CNS Pipeline

Biogen has signed a brace of collaborations to expand its central nervous system (CNS) pipeline, adding new candidates for Alzheimer’s, multiple sclerosis and other neurological diseases. The first...

Lilly and AC Immune to Develop Tau-Targeting Alzheimer’s Drug

Eli Lilly has paid $81m to develop drugs targeting aggregation of tau proteins associated with Alzheimer’s with Swiss biotech AC Immune, as focus shifts away from therapies targeting clumps of amyloid...

CarThera to Develop Ultrasound-Based Devices to Treat Brain Bisorders

French company CarThera has raised €9 million in its Series B funding round to help it develop ultrasound-based medical devices to treat brain disorders and overcome the challenges of the blood-brain ...

New Alzheimer’s cure to enter clinical trials

The first drug candidate from Eisai and University College London (UCL)’s drug discovery collaboration is to enter Phase I clinical trials for Alzheimer’s disease (AD) early next year. The candidat...